Year: 2021

news_6

CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

- Company Receives $10 Million Milestone Payment from Kissei Pharmaceutical Co., Ltd. - IRVINE, Calif.--(BUSINESS WIRE)--#CG0070--CG Oncology, Inc., a clinical-stage...